



JUL 11 2012

JUL 17 2012

RADM William S. Stokes, Director
Interagency Center for the Evaluation
of Alternative Toxicological Methods
National Toxicology Program
National Institutes of Environmental Health Sciences
U.S. Department of Health and Human Services
P.O. Box 12233
Research Triangle Park, NC 27709

Dear RADM Stokes:

This letter is in response to Dr. Linda Birnbaum's letter of February 1, 2012, to the Occupational Safety and Health Administration (OSHA), in which she forwarded the recommendations for the LUMI-CELL Estrogen Receptor BG1Luc Estrogen Receptor Transcriptional Activation test method from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).

Sections 4(a) and 4(d) of the ICCVAM Authorization Act require agencies to review ICCVAM test method recommendations and notify ICCVAM in writing of their findings, including identification of the relevant test methods for which the ICCVAM test recommendations may be added or substituted.

The received document was reviewed by staff in OSHA's Directorate of Standards and Guidance. As you may know, OSHA does not require or enforce toxicity testing as a part of its regulatory activities. At this time, we have no relevant test methods for which the ICCVAM recommendations may be added or substituted. However, OSHA appreciates the continued work by ICCVAM to promote the development and use of alternative test methods.

Thank you for your valuable work in this field. We look forward to continued participation on the ICCVAM.

Sincerely,

/s/

David Michaels, PhD, MPH